22q11.2 Deletion Syndrome Market Size in the 7MM is expected to sour at a CAGR of 41.9% during the forecast period (2021–2030) | DelveInsight
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some facts of 22q11.2
Deletion Syndrome Market are:
- In 2020, the total prevalent cases of
22q11.2 deletion syndrome were 196,476
in the 7MM. The United States,
in the same year, accounted for 83,326
cases, the highest prevalence of 22q11.2 deletion syndrome cases in the
7MM, accounting for approximately 42%
of the total 7MM cases in 2020.
- Among the EU-5 countries, the highest
number of cases of 22q11.2 deletion syndrome were in Germany and the least in Spain
in 2020.
- 22q11.2 deletion syndrome is often
underdiagnosed and misdiagnosed, as the symptoms vary from patient to
patient. In the EU-5 countries, the total diagnosed prevalent cases of
22q11.2 deletion syndrome were 35,203
in 2020.
·
22q11.2 deletion syndrome is a multisystem disorder characterized
by several physical, behavioral and psychiatric disorders. In the 7MM, of the
focused age-group
6 to 12 and 13 to 17 years, the diagnosed prevalent cases of 22q11.2 deletion syndrome with
Behavioral and Psychiatric Phenotypes were 36,702,
in 2020.
Request
for Sample Page: https://www.delveinsight.com/sample-request/22q112-deletion-syndrome-market
22q11.2
Deletion Syndrome is a condition that develops because of chromosome defects and is
a complex, multi-organ disorder noted for its varying severity and penetrance
among those affected. As per several studies, it is the most common chromosomal
microdeletion reported in humans.
The name of the syndrome denotes the missing piece of chromosome
22. It is located at a specific place on that chromosome called q11.2. Most of
the time, 22q11.2 Deletion syndrome results from a new genetic deletion that
occurs when a baby is conceived. This is called a de novo deletion and occurs randomly
in either the mom’s egg or the dad’s sperm. Apart from this, in around 1 in 10
cases (10%), the 22q11.2 Deletion is passed on to a child by a parent who has
DiGeorge syndrome.
Scope of the 22q11.2
Deletion Syndrome Market Report:
- The report covers the descriptive
overview of 22q11.2 Deletion Syndrome, explaining its causes, signs and
symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided
into the 22q11.2 Deletion Syndrome epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of
both the current and emerging therapies for 22q11.2 Deletion Syndrome are
provided, along with the assessment of new therapies, which will have an
impact on the current treatment landscape
- A detailed review of 22q11.2 Deletion
Syndrome market; historical and forecasted is included in the report,
covering drug outreach in the 7MM
- The report provides an edge while
developing business strategies, by understanding trends shaping and
driving the global 22q11.2 Deletion Syndrome market
Request
for Sample Page: https://www.delveinsight.com/sample-request/22q112-deletion-syndrome-market
Some
of 22q11.2
Deletion Syndrome Companies are:
·
Zynerba Pharmaceuticals
·
Enzyvant
·
Roivant Sciences
·
Sumitomo Dainippon Pharma
·
And Many Others
Some
of 22q11.2
Deletion Syndrome Therapies are:
·
Zygel (ZYN002)
·
RVT-802
·
And Many Others
Request
for Sample Page: https://www.delveinsight.com/sample-request/22q112-deletion-syndrome-market
Table of Contents:
1. Key Insights
2. Executive Summary
of 22q11.2 Deletion Syndrome
3. Competitive
Intelligence Analysis for 22q11.2 Deletion Syndrome
4. 22q11.2 Deletion
Syndrome: Market Overview at a Glance
5. 22q11.2 Deletion
Syndrome: Disease Background and Overview
6. Patient Journey
7. 22q11.2 Deletion
Syndrome Epidemiology and Patient Population
8. Treatment
Algorithm, Current Treatment, and Medical Practices
8.1. 22q11.2 Deletion Syndrome Treatment and Management
8.2. 22q11.2 Deletion Syndrome Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of
22q11.2 Deletion Syndrome Treatment
11. Marketed
Products
List to be continued
in report
12. Emerging
Therapies
List to be continued
in report
13. 22q11.2 Deletion
Syndrome: Seven Major Market Analysis
14. Attribute
analysis
15. 7MM: Market
Outlook
16. Access and
Reimbursement Overview of 22q11.2 Deletion Syndrome
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight
Capabilities
22. Disclaimer
Some of Newly Launched Report:
·
Neuromodulation
Devices market
·
Neurostimulation
Devices market
·
Hernia
repair devices market
About Delveinsight:
DelveInsight Business Research is a leading Market
Research, and Business Consultant focused purely on Healthcare. It
helps pharma companies by providing them with end-to-end services to solve
their business problems.
Get hold of all the Pharma and healthcare market research
reports on our market research subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business
Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Comments
Post a Comment